

Award Number:
W81XWH-10-1-0189

TITLE:
Hetero-bivalent Imaging Agents for Simultaneous Targeting Prostate-Specific Membrane Antigen (PSMA) and Hepsin

PRINCIPAL INVESTIGATOR:
Youngjoo Byun, Ph. D.

CONTRACTING ORGANIZATION:
**Korea University 'FYgYUfW 'UbX'6 i g]bYgg: ci bXU]cb
Yeongi-gun, Chungnam 339-700, South Korea**

REPORT DATE:
September 2012

TYPE OF REPORT:
Annual
.
.

Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.

1. REPORT DATE FAY 01 2012		2. REPORT TYPE Annual		3. DATES COVERED 1 Sep 2011 – 31 Aug 2012	
4. TITLE AND SUBTITLE Hetero-bivalent Imaging Agents for Simultaneous Targeting Prostate-Specific Membrane Antigen (PSMA) and Hepsin				5a. CONTRACT NUMB	
				5b. GRANT NUMBER W81XWH-10-1-0189	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Youngjoo Byun, Ph. D. E-Mail: "1d{ wp3B nqtgc0e0m				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Korea University Research and BusinessFoundation Yeongi-gun, Chungnam 339-700, South Korea				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The hypothesis of the original proposal was to improve the sensitivity and accuracy of prostate cancer diagnosis by targeting simultaneously PSMA and hepsin, which are highly expressed in advanced and metastatic prostate cancer. In Year 2, we successfully established the solid-phase synthetic strategy of PSMA-hepsin peptide conjugates and synthesized key intermediates to conjugate with imaging probes including optical dyes and radionuclides. The synthesized dual-targeting conjugates consist of PSMA-binding ligand (Lys-urea-Glu) and hepsin-binding ligands derived from the IPLLVVPLGGSSK peptide and indole-5-caboximidamide. In silico docking studies of compound library with human hepsin identified potential hits which can be utilized as hepsin-binding scaffolds. The synthesized conjugates will be labeled with radionuclides/optical dyes and evaluated in vivo in Year 3.					
15. SUBJECT TERMS PSMA, Hepsin, Prostate Cancer, Molecular Imaging					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			USAMRMC
			UU	13	19b. TELEPHONE NUMBER (include area code)

A. Introduction

Prostate cancer (PCa) is the leading cancer in the U.S. population and the second leading cause of cancer death in men. (1) An estimated 241,740 new cases and 28,170 deaths of prostate cancer will occur in the US during 2012, according to the statistics of American Cancer Society (www.cancer.org). Even if current detection methods of PCa using prostate-specific antigen (PSA) testing have advanced significantly for the diagnosis of patients with PCa, the controversy on PSA is currently still being debated. There have been several recent clinical reports whether PSA testing is an efficient biomarker in diagnosing the prostate cancer and reducing prostate cancer deaths. Two studies in the European countries showed that men who receiving PSA screening can lower the risk of death from prostate cancer while the study in the USA did not show any difference between PSA screening group and non-PSA group statistically. (2-4) Due to the lack of PSA specificity for PCa, there has been an increase of unnecessary biopsies/treatments of what would be benign or indolent disease. Therefore, there is an urgent need to explore new biomarkers for early and precise detection of PCa, in particular small lesions, i.e., recurrent tumors in the surgical bed, local lymph node invasion and other subtle manifestations of the disease in men. PSMA (prostate-specific membrane antigen) and hepsin are on the line as clinical biomarkers of PCa due to the fact that they are highly expressed in metastatic prostate cancer

PSMA is a type II integral membrane metalloprotease that has abundant and restricted expression on the surface of prostate carcinomas, particularly in androgen-independent, advanced and metastatic disease. (5,6) PSMA possesses the criteria of an ideal target for immunotherapy and diagnosis, i.e., expression primarily restricted to the prostate, abundantly expressed as protein at all stages of the disease, presented at the cell surface but not shed into the circulation, and association with enzymatic or signaling activity.(6) SPECT-CT scan of PCa using ^{111}In -capromab pendetide (Cyt-356, ProstaScint), a [^{111}In]-labeled monoclonal antibody to PSMA, showed promise in the clinic for identifying candidates for salvage radiotherapy. (7, 8)

Because of the important functions of PSMA for PCa, we have designed and prepared PSMA-based imaging probes to evaluate its biological activity *in vivo* in a variety of conditions using PET, SPECT and optical dyes. (9) According to the recent PSMA crystal structures in complex with several ligands, the PSMA active site consists of two distinct sub-pockets, which form a 'glutamate-sensor' S1' site and an amphiphilic S1 site. The cylinder-like $\sim 20\text{\AA}$ deep tunnel region exists adjacent to the S1 site and penetrates the surface of the enzyme.(10) We have taken advantage of the structural freedom provided by the S1 pocket to introduce imaging moieties. The lysine in the S1 binding site was chosen as a core scaffold in order to 1) take advantage of the many radiohalogenation methods and radiohalogenated prosthetic groups developed previously for reaction with the ϵ -amino group of lysine residues, and 2) increase the structural diversity of urea-based PSMA inhibitors. (10, 11) Among several lysine-urea-glutamate (Lys-urea-Glu) analogs, 2-[3-[1-carboxy-5-(4-[^{125}I]iodo-benzoylamino)-pentyl]-ureido]-pentanedioic acid ([^{125}I]DCIBzL, $\text{IC}_{50}=0.01\text{ nM}$) and [$^{99\text{m}}\text{Tc}$]L1 ($\text{IC}_{50}=10\text{ nM}$) exhibited the promising properties for PSMA imaging *in vivo*.(10, 11) Armed with X-ray information and molecular modeling dynamics, we have also demonstrated that the bulky labeling groups including radiometal-chelators and optical-dyes can be conjugated with the Lys-urea-Glu moiety by linking with an optimal spacer, which occupies the $> 20\text{\AA}$ tunnel region. (10) The bulky SPECT/Optical PSMA-


imaging probes with a spacer length of $> 20\text{\AA}$ demonstrated potent PSMA-inhibitory activities *in vitro* as well as selective uptake into PSMA-positive tumors *in vivo*. (12)

Hepsin also exhibited staining predominantly in the plasma membrane and was preferentially expressed in neoplastic prostate over benign prostate.(13) In addition, the mRNA level of *hepsin* was elevated in $\sim 90\%$ of PCa specimens and was > 10 -fold higher in metastatic PCa than in normal prostate or benign prostatic hyperplasia (BPH). Hepsin is composed of 413 amino acids and a 373-residue is in extracellular region. The extracellular 255 amino acids at the C-terminus, so called serine protease domain, are highly homologous among typeII trypsin-like serine proteases.(14) There have no report on hepsin inhibitors with a nanomolar IC_{50} value, which is considered as a cut-off value of promising compounds for *in vivo* molecular imaging. Valency is the number of separate connections that one microscopic entity makes with another (16). In general, higher valency yields higher affinity. Recently, Kelly et. al reported the successful detection of prostate cancer at the *in vivo* animal studies using hepsin-targeted multivalent nanoparticles. (17) Moderately-potent peptide (IPLVVPL, 120 nM) conjugated with fluorescent-labeled nanoparticle improved binding affinity/avidity for hepsin and exhibited fluorescent signal *via* FACS by >10 -fold higher than the peptide alone.

Our hypothesis of the original proposal was that more sensitive and potent PCa imaging agents can be developed by dual-targeting of PSMA and hepsin which are highly expressed in PCa, each with an extracellular active site. Their cell expression and high expression in the tumors, easy access of imaging probes to the target site and high affinity for PCa-cells through heterobivalency can be possible. The proposed imaging probes contain a PSMA-binding ligand and a hepsin-binding ligand linked by an optimal spacer, and will possess enhanced affinities/avidities for PCa compared to the corresponding monovalent PSMA or hepsin ligands.

B. Specific Aims in Year 2

Figure 1




We hypothesized that the sensitivity and accuracy of PCa diagnosis can be improved by dual-targeting of PSMA and hepsin. We proposed heterobivalent conjugates of PSMA/hepsin-binding ligands labeled with optical dyes, positron- and gamma-emitting nuclides, in order to provide agents with enhanced affinity/avidity for PCa. The PSMA-binding ligand moiety of proposed conjugates is Lys-urea-

Glu, which has been used as the key S1'-probing moiety for preparation of our PSMA imaging probes. We proposed three hepsin-binding ligands based on the small molecules reported as weak to moderate hepsin inhibitors. These are indole-5-carboximidamide scaffold (ACIC) crystallized with hepsin (17) and IPLLVVPL peptide obtained by phage-display microarrays.(16) The ultimate goals throughout the 2-yr project period was to synthesize the heterobivalent conjugates of the PSMA-ligand (Lys-urea-Glu) with two hepsin ligands (indole-5-carboximidamide and IPLLVVPL peptide) and to evaluate their *in vitro* biological properties for *in vivo* animal imaging studies with optical- or radionuclide-labeled conjugates in Year 3. During the 2nd year period, we established the synthetic strategies of ACIC and IPLLVVPL peptides and successfully synthesized key intermediates for the synthesis of hetero-bivalent conjugates as shown in Figure 1. The hetero-bivalent conjugates consist of three moieties that possess distinct roles for simultaneous targeting of PSMA and hepsin: (1) a high-affinity urea-based PSMA ligand, Lys-urea-Glu, (2) hepsin ligands derived from indole-5-carboximidamide or IPLLVVPL peptide, and (3) a nucleophilic functional group to be coupled with radionuclides, i.e., ¹²⁵I or ¹⁸F, or optical dyes.


C. Accomplishments in Year 2

Scheme 1. Synthesis of ACIC



Reagents: (a) Fmoc-OSu, (b) 2-hydroxybenzeneboronic acid, Pd(OH)₂, (c) i: AcCl, pyridine/DCM, ii: AlCl₃, dichlorobenzene, (d) EtOH, TEA, (e) PPA, 155 °C, (f) NH₄Cl, Al(CH₃)₃, p-xylene, reflux, (g) NaNO₂, 6N-HCl

Scheme 2




Reagents and conditions: (a) 2-hydroxybenzeneboronic acid, Cs₂CO₃, DMF/H₂O, Pd(PPh₃)₄, 100 °C, (b) Fmoc-OSu, DMF, (c) acetyl chloride, dichloromethane/pyridine (1:1), (d) AlCl₃, dichlorobenzene, 130 °C

1. Synthesis of ACIC-derived hepsin ligand

The original synthetic route to hepsin-binding ligand 2-(4'-(aminomethyl)-2-hydroxybiphenyl-3-yl)-6-chloro-1H-indole-5-carboximidamide (ACIC) is outlined in Scheme 1. ACIC is an analogue derived from a weak hepsin inhibitor (2-hydroxybiphenyl-3-yl-6-chloro-1H-indole-5-carboximidamide), of which crystal structure in complex with hepsin was reported. (18) Reaction of commercial 4-bromobenzylamine with Fmoc-OSu afforded the Fmoc-protected **35** in 69% yield. However, coupling of **35** with 2-hydroxybenzeneboronic acid *via* palladium-catalyzed Suzuki reaction gave **36** in low yield (< 20%) because of Fmoc-deprotection under the basic conditions. We investigated an alternative route to synthesize Fmoc-

protected 2'-hydroxybiphenyl analog **36-2** by employing the Suzuki coupling in the 1st step and subsequent Fmoc-deprotection as shown in Scheme 2. Compound **36-2** was prepared in a yield of 57% from 4-bromobenzylamine. Acetylation of **36-2** by the treatment of acetyl chloride afforded **36-3** in high yield. However, Fries rearrangement of **36-3** with AlCl_3 in dichlorobenzene at 130 °C did not afford the 2'-hydroxyacetophenone **36-4**. Ester moiety of **36-3** was hydrolyzed under Fries rearrangement conditions to regenerate **36-2**. We observed the same phenomenon in the 4'-hydroxybiphenyl analog, implying that bulkiness of Fmoc group may affect the rearrangement of the acetyl moiety. Therefore, we replaced Fmoc with acetyl (COCH_3) as protecting group of benzyl amine. The modified synthetic procedure of the hepsin-binding ligand 2-(4'-(aminomethyl)-2-hydroxybiphenyl-3-yl)-6-chloro-1H-indole-5-carboximidamide (ACIC) was outlined in Scheme 3.

Scheme 3. Modified synthetic procedure of ACIC




Reagents: (a) 2-hydroxybenzeneboronic acid, Cs_2CO_3 , $\text{Pd}(\text{PPh}_3)_4$, $\text{DMF}/\text{H}_2\text{O}$, 100 °C, (b) AcCl , pyridine/DCM (1/1), (c) AlCl_3 (4 eq), dichlorobenzene, (d) EtOH , TEA, (e) PPA, 155 °C, (f) NH_4Cl , $\text{Al}(\text{CH}_3)_3$, p-xylene, reflux, (g) NaNO_2 , 6N-HCl

Suzuki-coupling reaction of 4-bromobenzylamine with 2-hydroxybenzeneboronic acid using $\text{Pd}(\text{PPh}_3)_4$ as a palladium-catalyst afforded the compound **41** in 78% yield. Acetylation of **41** by the treatment of acetyl chloride in pyridine/dichloromethane gave **42** in 62% yield. Fries rearrangement of acetyl moiety to the *ortho*-position occurred successfully by reacting **41** with AlCl_3 (2 eq) in dichlorobenzene at 130 °C for 24 hr. $^1\text{H-NMR}$ studies confirmed that the acetyl moiety of **43** appeared at 2.58 ppm while that of **42** at 2.11 ppm. 2-Chloro-5-hydrazinylbenzimidamide **38** was synthesized from 4-amino-2-chlorobenzonitrile in 2 steps in 35 % yield. Addition of 4-amino-2-chlorobenzonitrile to a mixture of ammonium chloride in p-xylene and trimethylaluminium (1M solution in n-heptane) at 0 °C, followed by reflux, resulted in formation of an amidine analog. The amidine was converted into the hydrazine **38** by the treatment of NaNO_2 and subsequent SnCl_2 . Condensation of **43** with the hydrazine **38** gave asymmetric hydrazone **44**. Fisher indolization of **44** mediated by polyphosphoric acid (PPA) afforded **45** in 30% yield. After deprotection of acetyl group of **45**, coupling of **45** with **32** will give ACIC-based conjugates **10-18**, which are planned in Year 3.

2. Synthesis of conjugate of PSMA with IPLLVVPLGGSSK-peptide ligand

2.1. Hepsin-targeting IPLLVVPLGGSSK

Scheme 4. IPLLVVPLGGSSK synthesis




The IPLLVVPLGGSSK peptide, which has an affinity of 190 nM for hepsin-expressing PC3 cells (HPN-PC3 cells), was identified by phage selection method by Kelly et al. (17). The conjugate of the peptide with nanoparticles increased binding affinity for HPN-PC3 cells compared to the peptide alone. Compound IPLLVVPLGGS(tBu)S(tBu)K was prepared as shown in Scheme 4. Microwave-assisted peptide technology has been successfully applied for the synthesis of IPLLVVPLGGS(tBu)S(tBu)K. The allyloxycarbonyl (Alloc) protecting group of C-terminus lysine was used as a starting material. The amine group in the ϵ -position of the lysine was intended to conjugate with PSMA-binding ligand while that in the α -position of the lysine or N-terminus isoleucine with the imaging prosthetic groups such as optical dyes and radionuclides. The alloc group was removed by the treatment of phenylsilane and tetrakis(triphenylphosphine)palladium in dichloromethane. Treatment of **52** with a mixture of acetic acid/trifluoroethanol/dichloromethane (1/1/4) for 2 hr removed the key intermediate **53**, IPLLVVPLGGS(tBu)S(tBu)K which was confirmed by ESI-mass spectrum (M+H peak: 1501.8).

2.2. Synthesis of Boc- β -glutamic acid-bis-NHS ester


The β -glutamic acid shown in Scheme 5 was chosen as a linker of the PSMA/hepsin-targeting moieties as well as a functional group to couple with an imaging probe in order to avoid the formation of structural isomers. The

Scheme 5. Boc- β -glutamic acid-bis-NHS ester



two carboxylic acid groups of β -glutamic acid are chemically equivalent whereas those of α -glutamic acid are not. The amine group of β -glutamic acid was protected with Boc by reacting β -glutamic acid with Boc anhydride in water/dioxane in a yield of 63%. N-hydroxysuccinimide (NHS) activated ester was synthesized by reacting **61** with NHS using EDAC as a coupling agent in 60% yield. $^1\text{H-NMR}$ and ESI-MS confirmed the Boc- β -glutamic acid-bis NHS ester **62**.

Scheme 6. The synthesis of PSMA-NHS ester




2.3. The synthesis of PSMA-NHS ester

The PSMA-NHS ester **64** shown in Scheme 6 is a versatile intermediate that can be used to couple with ligands of a variety of target proteins such hepsin and extracellular metalloproteases. Compound **63** was synthesized by following the procedure we have reported. (10, 12) Conversion of **63** into **64** was successfully achieved under basic conditions (pH: 8.5-9.0) in DMF. Reaction of PSMA-amine **63** with 3 equivalents of Boc- β -glutamic acid-bis-NHS ester **62** afforded **64** in 42% yield without any formation of dimer products. ESI-MS confirmed the formation of **64** with $[\text{M}+\text{H}]^+$ peak at 1041.2.

2.4. The synthesis of PSMA-Hepsin Conjugate (Scheme 7)

Scheme 7. Synthesis of PSMA-hepsin conjugate



Conjugation of **53** with **64** was achieved under the basic condition (DIPEA in DMF, pH=8.0-8.5). Subsequent removal of ^tBu by the treatment of trifluoroacetic acid (TFA) afforded the target compound **70** which contains PSMA-binding moiety (Lys-urea-Glu) and hepsin-binding moiety (IPLLVVPLGGSSK). The free amine (brown color in Scheme 7) of **70** will be utilized for coupling with optical dyes or radionuclides in Year 3. ESI-MS spectral data confirmed the molecular [M+H]⁺ ion peak at 2064.4 at the positive mode (see Figure 2).

Reaction of **70** with N-succinimidyl-4-

[¹²⁵I]iodobenzoate(S[¹²⁵I]IB) or N-succinimidyl-4-[¹⁸F]fluorobenzoate(S[¹⁸F]FB) in the presence of TEA will provide the corresponding radiolabeled analogs for *in vivo* imaging studies in Year 3. For the synthesis of non-radiolabeled compounds, nonradioactive SIB and SFB will be used instead of S[¹²⁵I]IB and S[¹⁸F]FB at the final





Figure 2. ESI-MS spectrum of compound **70**

step. In the similar way, optical dyes such as LI-COR dye (near infra red fluorescence dye) and FITC will be conjugated with **70** to produce optical imaging probes for *in vivo* studies.

3. *In silico* virtual screening of compound library with human hepsin

Figure 3. Representative hits from *in silico* docking studies of compound library with hepsin



* IC_{50} s of compounds 2 and 8 were adapted from the data published by Chevillet et. al.

and Momany-Rone partial charge calculation. LibDock module of DS 3.0 is compatible for the high-throughput screening of compound library *in silico*. The default parameters (number of hotspots: 100, docking tolerance:

0.25) were used. Based on LibDock Score, the potential hit compounds were selected for *in vitro* screening and further structural modification of the identified hits will be planned in Year 3. More than 20 compounds from the LOPAC¹²⁸⁰ showed the higher binding energies than the known hepsin inhibitors (compound 2 & 8 in Figure 3). Figure 3 summarizes the chemical structures of the representative hits with their *in silico* binding energies to hepsin. LOPAC 958 (Nelfinavir), a HIV-1 protease inhibitor, were as strong as Ac-KQLR-methylketone. Nelfinavir was reported to induce growth arrest and apoptosis of human prostate cancer cells such as LNCaP, DU 145 and PC-3 cells. (21) Anthraquinone-containing analogs (LOPAC937 and LOPAC1057 in Fig 3) exhibited high binding energies to




Figure 4. 2D-diagram of hepsin-LOPAC 937 interaction

hepsin, indicating that anthraquinone moiety can be utilized as scaffold to design new PSMA-hepsin conjugates. The 2D-diagram between LOPAC 937 and hepsin in Figure 4 showed that the LOPAC 937 interact the three amino acids (Ser 353, His 203 and Asp 257) in the triad system of the hepsin active site. Ser 353 and Asp 257 make strong intermolecular hydrogen bonds with amine and phenol moieties of LOPAC937, respectively. In addition, tryptophan-derived LOPAC621 and glutamate-derived LOPAC17 have higher binding energies compared to the reported hepsin inhibitors (compounds **2** & **8**), which can be utilized as hepsin-binding scaffolds in the future.

D. Research Plan for the 3rd Year

During the 2nd year of the award, we successfully established the solid-phase synthetic strategy of PSMA-hepsin peptide conjugates and synthesized key intermediates to conjugate with imaging probes including optical dyes and radionuclides. We plan to prepare labeled conjugates of PSMA-hepsin as imaging probes using the current key intermediate and to perform *in vivo* animal optical and SPECT-CT imaging studies in Year 3. In addition, we will synthesize new conjugates of PMSA with the hepsin ligands which identified from *in silico* docking studies. They exhibited strong binding affinities to hepsin compared to the low M.W. hepsin ligands which we designed in the original proposal. We believe that the continued funding for the 3rd year could allow us to get the point of viable, novel agents to image prostate cancer *via* dual-targeting of PSMA and hepsin. The principal investigator successfully established his own lab at Korea University (KU) and recruited the post-doctoral fellow and the graduate student who will carry out the synthesis, *in silico* docking studies, and *in vitro* assays. Animal imaging studies will be performed at Johns Hopkins University (JHU) under the direction of Dr. Martin G. Pomper. KU and JHU made the research agreement and the subcontract starting from 2012. With the continued funding in Year 3, we can accumulate the scientific data and publish them in a prestigious journal.

E. Milestone in Year 3: *Synthetic chemistry, radiochemistry and biological evaluation*

We will continue major on-going efforts to synthesize the non-radiolabeled conjugates of PSMA-hepsin at KU. Dr. Jianbo Chen and the graduate student at KU will carry out the synthesis, *in silico* docking studies, and *in vitro* assays under the supervision of PI. Dr. Chen joined Dr. Byun's lab in April, 2012 and got 100% salary support in Year 2 of this award. Because of his expertise and excellent performance, he was selected as a recipient of the salary-supported research professor program from KU and will receive 50% of his salary from KU from 09/01/2012 to 08/31/2013. Even if his salary-based FTE is 50% in Year 3, his dedication of 100% time efforts to the project will be continued. In Year 3, the remaining personnel budget will be allocated to the graduate student, who will join Dr. Byun's lab in November, 2012. During the Year 3 period (2012-2013), KU scientists will complete the synthesis of non-radiolabeled conjugates as well as their biological evaluations *in vitro*. JHU researchers will perform radio-synthesis and *in vivo* animal studies. Drs. Pomper and Mease at JHU, collaborators of this project, will carry out the radiolabeling of the PSMA-hepsin conjugates and *in vivo* molecular imaging studies.

Reference Cited:

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. *CA Cancer J. Clin.* 2003; 53: 5-26.
2. Schroder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11years of follow-up. *New Engl. J. Med.* 2012; 366: 981-990.
3. Heijnsdijk EA, Wever, EM, Auvinen A, et al. Quality-of-life effects of prostate-specific antigen screening. *New Engl. J. Med.* 2012; 367: 595-605.
4. Vickers AJ, Till C, Tangen CM, Lisa H, Thompson IM. An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. *J. Natl. Cancer I.* 2011; 103: 462-469.
5. Schulke N, Varlamova OA, Donovan GP, et al. The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. *Proc. Natl. Acad. Sci. U S A* 2003; 100: 12590-5.
6. Huang X, Bennett M, Thorpe PE. Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen. *Prostate* 2004; 61: 1-11.
7. Chang SS, Heston WD. The clinical role of prostate-specific membrane antigen (PSMA). *Urol. Oncol.* 2002; 7: 7-12.
8. Koontz BF, Mouraviev V, Johnson JL, et al. Use of Local ¹¹¹In-Capromab Pendetide Scan Results to Predict Outcome After Salvage Radiotherapy for Prostate Cancer. *Int. J. Radiat. Oncol, Biol, Phys* 2008; 71: 358-61.
9. Pomper MG, Musachio JL, Zhang J, et al. ¹¹C-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase). *Mol. Imaging* 2002; 1: 96-101.
10. Banerjee SR, Foss CA, Castanares M, et al. Synthesis and Evaluation of Technetium-99m- and Rhenium-Labeled Inhibitors of the Prostate-Specific Membrane Antigen (PSMA). *J Med Chem* 2008; 51: 4504-17.
11. Chen Y, Foss CA, Byun Y, et al. Radiohalogenated Prostate-Specific Membrane Antigen (PSMA)-Based Ureas as Imaging Agents for Prostate Cancer. *J. Med. Chem.* 2008; 51: 7933-43.
12. Banerjee SR, Pullambhatla M, Byun Y, et al. Sequential SPECT and Optical Imaging of Experimental Models of Prostate Cancer with a Dual Modality Inhibitor of the Prostate-Specific Membrane Antigen. *Angew. Chem. Int. Edit.* 2011; 50: 9167-9170
13. Dhanasekaran SM, Barrette TR, Ghosh D, et al. Delineation of prognostic biomarkers in prostate cancer. *Nature (London, U K)* 2001; 412: 822-6.
14. Somoza JR, Ho JD, Luong C, et al. The Structure of the Extracellular Region of Human Hepsin Reveals a Serine Protease Domain and a Novel Scavenger Receptor Cysteine-Rich (SRCR) Domain. *Structure (Cambridge, MA, U S)* 2003; 11: 1123-31..
15. Tweedle MF. Adventures in multivalency, the Harry S. Fischer memorial lecture CMR 2005; Evian, France. *Contrast Media Mol. Imaging* 2006; 1: 2-9.
16. Kelly KA, Setlur SR, Ross R, et al. Detection of Early Prostate Cancer Using a Hepsin-Targeted Imaging Agent. *Cancer Res.* 2008; 68: 2286-91.

17. Katz BA, Luong C, Ho JD, et al. Dissecting and Designing Inhibitor Selectivity Determinants at the S1 Site Using an Artificial Ala190 Protease (Ala190 uPA). *J. Mol. Biol.* 2004; 344: 527-47.
18. Mackman RL, Katz BA, Breitenbucher JG, et al. Exploiting Subsite S1 of Trypsin-Like Serine Proteases for Selectivity: Potent and Selective Inhibitors of Urokinase-Type Plasminogen Activator. *J. Med. Chem.* 2001; 44: 3856-71.
19. Herter S, Piper DE, Aaron W, et al. Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers. *Biochem. J.* 2005; 390: 125-136.
20. Chevillet JR, Park GJ, Bedalov A, Simon JA, Vasioukhin VI. Identification and characterization of small-molecule inhibitors of hepsin. *Mol. Cancer Ther.* 2008; 7: 3343-51.
21. Yang Y, Ikezoe T, Takeuchi T, et al, HIV-1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells in vitro and in vivo in conjugation with blockade of androgen receptor STAT3 and AKT signaling. *Cancer Sci.* 2005; 96: 425-433.